To determine the effects of JZG on hepatic steatosis, two approaches were employed in this study: (1) an in vivo model involving HFD-fed rats and (2) an in vitro model by treatment with FFA, LXRα agonist (T090), and siRNA targeting LXRα. This evidence concerns the gene NR1H3 and Hepatic steatosis.